Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

@article{Collet2009CytochromeP2,
  title={Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study},
  author={Jean-Philippe Collet and Jean-S{\'e}bastien Hulot and A Pena and Eric Villard and J B Esteve and Johanne Silvain and Laurent Payot and Delphine Brugier and Guillaume Cayla and Farzin Beygui and Gilbert Bensimon and Christian Funck-Brentano and Gilles Montalescot},
  journal={The Lancet},
  year={2009},
  volume={373},
  pages={309-317}
}

Figures and Tables from this paper

Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China
TLDR
There was no significant association between the carrier status and the clinical outcome at 1, 6, and 12 months of genotype-guided antiplatelet therapy, and new light is shed on the important benefit of testing CYP2C19 polymorphisms before prescribing clopidogrel in patients treated with drug-eluting stent implantation after PCI.
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
TLDR
CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding andMultivariate analysis confirmed the independent association of CYP2C 19*17 allele carriage with platelet aggregation values and the occurrence of bleeding.
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease
TLDR
It is suggested that antiplatelet response to clopidogrel in the late phase depends on the CYP3A5 polymorphism in PM with CYP2C19.
CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population
TLDR
PM patients had an increased risk of ST, death, and MI after coronary stent placement in a Chinese population, and multivariate analysis confirmed the independent association of CYP2C19 loss-of-function allele carriage with ST.
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
TLDR
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes, and patients with the CYP2C 19*2 variant were more likely to have a cardiovascular ischemic event or death during 1 year of follow-up.
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome
TLDR
CYP 2C19*2 is associated with reduced clopidogrel antiplatelet activity and might be an important marker for poor prognosis of ACS.
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
TLDR
A review of the principal studies contributing to establish the relationship between CYP2C19*2 polymorphism and adverse outcomes in high risk patients on clopidogrel treatment concludes that prospective studies are urgently needed to determine the clinical impact of a score that takes into account individual characteristics of patients.
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study
TLDR
CYP2C19 may exert a significant impact on the prognosis of PCI patients even in the era of newer-generation drug-eluting stents, and the optimal cut-off value of high OPR for major adverse thrombotic events was 266.
No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting
TLDR
Routine genotyping of ABCB1 C3435T polymorphisms should not be recommended for risk stratification in clopidogrel-treated patients undergoing percutaneous coronary intervention who are similar to those evaluated in the present study.
...
...

References

SHOWING 1-10 OF 60 REFERENCES
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
AIMS To investigate an association of responsiveness to clopidogrel loading dose with genotypes of cytochrome P450 (CYP) 2C19, other CYP isozymes and nongenetic factors in patients with coronary
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
TLDR
The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopsinogrel resistance in the clinical setting.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
TLDR
In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All?
TLDR
Analyses from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial suggest that clopidOGrel pretreatment 6 to 15 hours before PCI is necessary to significantly reduce CV events.
Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
TLDR
Interindividual variability in the platelet inhibitory response from clopidogrel occurs in patients undergoing elective coronary stenting, and patients with high pretreatment reactivity are least protected.
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention
TLDR
After loading with 600 mg of clopidogrel, the full antiplatelet effect of the drug is achieved after 2 hours, and Statins do not interfere with the level of platelet inhibition after this dose.
...
...